Literature DB >> 28598572

Searching for Novel Inhibitors of the S. aureus NorA Efflux Pump: Synthesis and Biological Evaluation of the 3-Phenyl-1,4-benzothiazine Analogues.

Tommaso Felicetti1, Rolando Cannalire1, Maria Sole Burali1, Serena Massari1, Giuseppe Manfroni1, Maria Letizia Barreca1, Oriana Tabarrini1, Bryan D Schindler2, Stefano Sabatini1, Glenn W Kaatz2, Violetta Cecchetti1.   

Abstract

Bacterial resistance to antimicrobial agents has become an increasingly serious health problem in recent years. Among the strategies by which resistance can be achieved, overexpression of efflux pumps such as NorA of Staphylococcus aureus leads to a sub-lethal concentration of the antibacterial agent at the active site that in turn may predispose the organism to the development of high-level target-based resistance. With an aim to improve both the chemical stability and potency of our previously reported 3-phenyl-1,4-benzothiazine NorA inhibitors, we replaced the benzothiazine core with different nuclei. None of the new synthesized compounds showed any appreciable intrinsic antibacterial activity, and, in particular, 2-(3,4-dimethoxyphenyl)quinoline (6 c) was able to decrease, in a concentration-dependent manner, the ciprofloxacin MIC against the norA-overexpressing strains S. aureus SA-K2378 (norA++) and SA-1199B (norA+/A116E GrlA).
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  NorA efflux pump; Staphylococcus aureus; antimicrobial resistance (AMR); inhibitors; medicinal chemistry

Mesh:

Substances:

Year:  2017        PMID: 28598572     DOI: 10.1002/cmdc.201700286

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  6 in total

1.  PLGA microsphere-based composite hydrogel for dual delivery of ciprofloxacin and ginsenoside Rh2 to treat Staphylococcus aureus-induced skin infections.

Authors:  Minghao Sun; Chune Zhu; Jieyu Long; Chao Lu; Xin Pan; Chuanbin Wu
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

2.  Clinically Approved Drugs Inhibit the Staphylococcus aureus Multidrug NorA Efflux Pump and Reduce Biofilm Formation.

Authors:  Saskia Zimmermann; Mareike Klinger-Strobel; Jürgen A Bohnert; Sindy Wendler; Jürgen Rödel; Mathias W Pletz; Bettina Löffler; Lorena Tuchscherr
Journal:  Front Microbiol       Date:  2019-12-03       Impact factor: 5.640

3.  1,3,4-Oxadiazole N-Mannich Bases: Synthesis, Antimicrobial, and Anti-Proliferative Activities.

Authors:  Lamya H Al-Wahaibi; Ahmed A B Mohamed; Samar S Tawfik; Hanan M Hassan; Ali A El-Emam
Journal:  Molecules       Date:  2021-04-07       Impact factor: 4.411

Review 4.  Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing.

Authors:  Natalie K Boyd; Chengwen Teng; Christopher R Frei
Journal:  Front Cell Infect Microbiol       Date:  2021-05-17       Impact factor: 5.293

Review 5.  The Continuing Threat of Methicillin-Resistant Staphylococcus aureus.

Authors:  Márió Gajdács
Journal:  Antibiotics (Basel)       Date:  2019-05-02

Review 6.  Efflux Pump Mediated Antimicrobial Resistance by Staphylococci in Health-Related Environments: Challenges and the Quest for Inhibition.

Authors:  Abolfazl Dashtbani-Roozbehani; Melissa H Brown
Journal:  Antibiotics (Basel)       Date:  2021-12-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.